ds-8895a
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2013 (NCT02004717)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ephrin type-A receptor 2INHIBITOR
EPHA2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ds-8895a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02252211 | Phase 1 | Sep 1, 2014 | Austin Health, Daiichi Sankyo, Ludwig Institute for Cancer Research |
| NCT02004717 | Phase 1 | Oct 1, 2013 | Daiichi Sankyo |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 2 | 1 | 1 | 2013 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1